Skip to main content

C4221016 A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib plus Pembrolizumab versus Placebo plus Pembrolizumab in Participants with BRAF V600E/K Mutation-positive Metastatic or Unresectable Locally Advanced Melanoma

NCT04657991

A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib plus Pembrolizumab versus Placebo plus Pembrolizumab in Participants with BRAF V600E/K Mutation-positive Metastatic or Unresectable Locally Advanced Melanoma

Associated Conditions

Melanoma

Principal Investigator

Sponsor

Pfizer

The purpose of this study is to learn about the effects of the study drugs, encorafenib and binimetinib plus pembrolizumab, and determine the best dose of encorafenib in combination with binimetinib and pembrolizumab that is safely tolerated and recommended for use in the Randomized Phase 3 part of the study. The study will also explore if the combination of encorafenib, binimetinib and pembrolizumab have beneficial effects on you and your cancer. By giving encorafenib and binimetinib with pembrolizumab, researchers want to see if the study drugs together work better as a combination.

This study is currently enrolling.